Patents Assigned to Pfizer Products Inc.
-
Patent number: 7297682Abstract: This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-?-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.Type: GrantFiled: May 6, 2004Date of Patent: November 20, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Robert J. Rafka, Colman B. Ragan, Douglas J. M. Allen
-
Patent number: 7259241Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.Type: GrantFiled: December 14, 2004Date of Patent: August 21, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Kim J. Stutzman-Engwall, Hamish McArthur
-
Publication number: 20070172877Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.Type: ApplicationFiled: March 15, 2007Publication date: July 26, 2007Applicants: Pfizer, Inc., Pfizer Products, Inc.Inventors: Michael Ellsworth, Martin Ficken, Brian Fergen, Cassius Tucker
-
Patent number: 7247628Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein.Type: GrantFiled: November 4, 2003Date of Patent: July 24, 2007Assignees: Pfizer, Inc., Pfizer Products, Inc.Inventors: Robert L. Dow, Marlys Hammond
-
Publication number: 20070161681Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.Type: ApplicationFiled: January 30, 2007Publication date: July 12, 2007Applicants: PFIZER INC., PFIZER PRODUCTS INC.Inventors: Anthony Marfat, Robert Chambers, Thomas Magee
-
Publication number: 20070154943Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.Type: ApplicationFiled: March 15, 2007Publication date: July 5, 2007Applicants: Pfizer, Inc., Pfizer Products, Inc.Inventors: Michael Ellsworth, Martin Ficken, Brian Fergen, Cassius Tucker
-
Publication number: 20070122367Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.Type: ApplicationFiled: November 21, 2006Publication date: May 31, 2007Applicants: PFIZER INC., PFIZER PRODUCTS INC.Inventors: Stuart Bradley, Eric Collington, Matthew Fyfe, Martin Procter, Colin Sambrook Smith
-
Publication number: 20070116722Abstract: The present invention provides a method of inducing an immune response against Campylobacter in an avian species, especially a domesticated avian species such as chicken, turkey, duck, goose and quail, by administering, in ovo, live cells of Campylobacter.Type: ApplicationFiled: November 22, 2004Publication date: May 24, 2007Applicant: PFIZER PRODUCTS INC.Inventors: Tonia Agin, Everett Rosey, Frederick Weber
-
Patent number: 7214677Abstract: The present invention relates to novel to P2X7 inhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: November 12, 2002Date of Patent: May 8, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Allen J. Duplantier, Chakrapani Subramanyam
-
Patent number: 7199243Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.Type: GrantFiled: November 24, 2003Date of Patent: April 3, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Scott W. Bagley, Thomas A. Brandt, Robert W. Dugger, William A. Hada, Cheryl M. Hayward, Zhengyu Liu
-
Patent number: 7183293Abstract: This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(?O)t—, where t is 0, 1, or 2; Y is ?C(R1a)—, where R1a is a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1–C4)alkyl; —(C2–C4)alkynyl; fluorinated-(C1–C3)alkyl; fluorinated-(C1–C3)alkoxy; —OR16; and —C(?O)NR22aR22b; R22a and R22b are defined as set forth in the specification; —RA and RB are each a member independently selected from the group consisting of H; F; CF3; —(C1–C4)alkyl; —(C3–C7)cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16 and R17 are defined as set forth in the specification; —RC and RD have the same meaning as defined above for RA and RB except that one of them must be —H, and they are selected independently of each other and of RA and RB; R1 and R2 are each a membType: GrantFiled: August 13, 2004Date of Patent: February 27, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Patent number: 7173052Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.Type: GrantFiled: December 2, 2004Date of Patent: February 6, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Stuart E. Bradley, Eric W. Collington, Matthew C. Fyfe, Martin J. Procter, Colin P. Sambrook Smith
-
Patent number: 7153872Abstract: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-?• signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.Type: GrantFiled: September 17, 2003Date of Patent: December 26, 2006Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Michael J. Munchhof, Laura C. Blumberg
-
Patent number: 7151110Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.Type: GrantFiled: September 23, 2005Date of Patent: December 19, 2006Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Michael J. Munchhof, Laura C. Blumberg
-
Patent number: 7138406Abstract: The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1–R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.Type: GrantFiled: July 8, 2003Date of Patent: November 21, 2006Assignees: Pfizer, Inc., Pfizer Products, Inc.Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson
-
Patent number: 7067664Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.Type: GrantFiled: May 30, 2000Date of Patent: June 27, 2006Assignees: Pfizer Inc., Pfizer Products Inc.Inventor: Yuhpyng L. Chen
-
Patent number: 7030242Abstract: This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate IC50s of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins).Type: GrantFiled: May 3, 2005Date of Patent: April 18, 2006Assignees: Pfizer Inc, Pfizer Products Inc.Inventors: Mark C. Noe, Michael A. Letavic, Louis S. Chupak, Kim F. McClure
-
Patent number: 7029683Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic hemolysin peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganisms.Type: GrantFiled: May 11, 2000Date of Patent: April 18, 2006Assignees: Pfizer Products, Inc., Agriculture Victoria Services Pty. Ltd., Pig Research and Development CorporationInventors: Michael Panaccio, Everett Lee Rosey, Detlef Hasse, Robert Gerard Ankenbauer
-
Publication number: 20060002945Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.Type: ApplicationFiled: September 7, 2005Publication date: January 5, 2006Applicants: Pfizer, Inc., Pfizer Products, Inc.Inventors: Mohamad Morsey, Tracy Brown
-
Patent number: 6979442Abstract: This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by administering such protein compositions to mammals. More particularly, the stabilized protein compositions of the present invention contain therapeutically effective amounts of G-CSF, such as bovine G-CSF, in combination with a stabilizing buffer, such as HEPES, TES or TRICINE, for treating and preventing infections, including mastitis, in cattle.Type: GrantFiled: August 12, 1999Date of Patent: December 27, 2005Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Peter C. Canning, Barbara J. Kamicker, Kasra Kasraian